Large cluster-randomized crossover study involving nearly 430,000 U.S. adults aged 65 years and older was published in the Journal of the American Medical Association (JAMA) Network Open...

A new long-term pandemic preparedness agreement between CSL Seqirus and PAHO’s Regional Revolving Fund builds on the parties’ seasonal influenza collaboration to support rapid and scalable...

CSL Seqirus will supply its differentiated influenza vaccine portfolio and, with long-term partner Sinergium Biotech, will localize vaccine filling and distribution. The partnership will...

FOR GLOBAL MEDIA CSL Seqirus will provide adjuvanted cell-based vaccines to support Canada, if an influenza pandemic is declared by the World Health Organization (WHO) Influenza viruses of...

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been...